corporation, * is attempting to get the National Library of Medicine (NLM) to increase, to a competitive level, the prices it charges for its indices and abstracts of biomedical information. Even though the long range impact is unpredictable, if Excerpta Medica is successful, such an increase certainly would affect most people who use the literature of the health sciences.
The NLM has been under attack previously by private industry,1.2 but the most recent conflict has reached the U.S. Senate. Last year, an amendment to the Public Health Service Act (S.8oo) was proposed that would have required the NLM to charge fees sufficient to recover the full costs "associated with (i) the administrative and intellectual preparation of information products; (ii) the creation and maintenance of systems for storage, retrieval, and dissemination of these products.' '3 Speaking at hearings on the amendment, Alex Adler, president of Excerpta Medica, read his company's position statement to the Senate Committee on Labor and Human Resources. Adler said, in part: Excerpta Medica finds its continued existence threatened by unfair competition from the United States Government through the NLM.
We believe the NLM is a vital institution. It supports many important projects and is recognized as a major repository of the world's biomedical information, accomplishments for which we are all justifiably proud.
However, the NLM's aggressive marketing of its indices and abstracts of biomedical information is in direct and unfair competition with private companies, including Excerpta Medica. NLM offers this information to the public, including commercial concerns, at far less than its real cost.
For example, its Medical Literature Analysis and Retrieval System (MEDLARS) is computerized and available on-line. MEDLARS-on-line, or MEDLINE, is financed mainly through taxpayer subsidies, since NLM charges its users only a minimal *Excerpta Medica is a U.S.-based subsidiary of Elsevier Science Publishers, The Netherlands. fee which is far below its full costs and substantially lower than private enterprise can realistically meet. ...the NLM's fees for MEDLINE, which have not increased since July of 1975, are currently less than V. of commercial rates for similar services. As evidence of this taxpayer subsidy, I should note that the NLM has just requested an additional appropriation of over $1.3 million this year (1981) alone simply to upgrade the MEDLARS system....
. . .In a free society increasingly dependent on information, no one entity, especially the government, should have exclusive control over information, its access or dissemination. Competition is the information user's insurance policy. It protects against price exploitation, access controls, unreliable content, limited selection, poor quality service, and lack of innovation. 4 Adler had much more to say, but these statements fairly represent his point of view. The NLM, having been put in a defensive position, has provided an extensive rebuttal to Excerpta Medica's position.s- 7 Adler's statement that the NLM "is in direct and unfair competition with private companies" is answered in an NLM fact sheet as follows:
NLM is not in direct competition ... because NLM's products and services do not duplicate those of any domestic producer. ... NLM is not in direct competition with the principal foreign bibliographic product (Excerpta Medica) because there is only about a 30-percent overlap in literature and because EM creates abstracts for all articles whereas NLM does not.· The central issue, however, is Adler's position that the NLM offers "information to the public, including commercial concerns, at far less than its real cost." Although this issue has been defended by NLM Director Martin M. Cummings, M.D.,s an NLM "white paper" provides interesting elaboration. It raises the question: "Should the charges for the National Library of Medicine's services be set artificially high in order to allow a foreign-owned company to 'compete' (i.e., make a profit)?'" NLM's negative response states that it:
...currently recovers approximately all the costs of accessing its online data bases (MEDLINE, CHEMLINE, etc.) and 70 percent of the full costs for these services. Full costs include all related computer and communication charges, all direct labor for system and network maintenance, all printing or duplicating charges, a Drug Intelligence and Clinical Pharmacy VOL 16 NOV 82 major portion of the cost of indexing the current medical literature as well overhead and indirect costs. NLM excludes from the cost base those costs which it would necessarily incur in carrying out its Congressionally mandated mission, namely, costs of literature acquisition (e.g., journal subscriptions), cataloging, storage (e.g., construction of the Library and its maintenance), and that portion of the cost of indexing the literature which would be required anyway in order to make it possible for a reference librarian at NLM to locate an article or articles that a reader needed. 7 At stake in the resolution of this controversy are the current services of the NLM. If we hypothesize that Excerpta Medica will be successful, there are a few questions that all those concerned need to think about:
1. What impact will this have on the leadership and present services at NLM? It should be borne in mind that the NLM began in 1836 as the Library of the Surgeon General's Office and over the years has demonstrated its ability to provide reliable content, comprehensive selection, high quality of service, and remarkable innovation. In contrast to the view expressed by Excerpta Medica, this has been done in the absence of competition as a motivating force. Nicholas E. Davies, M.D., wrote an exhaustive report of the NLM conflict. He cited a major accomplishment of the NLMthe introduction of MEDLARS in 1964. Davies stated: "A product of 15 years' planning, MEDLARS was the great bibliographic breakthrough of the generation."8 2. What effect will this have on all health science libraries throughout the world? It is well known that the demands on libraries for growth are on a collision course with ever-escalating costs of operations. NLM services are already a major expense for many libraries, so they can ill afford a significant increase. One possible consequence could be that the users of health science libraries will be denied access to a segment of the biomedical literature. To quote one librarian: " ... Index Medicus is regarded as an essential tool. If its price is drastically increased, librarians will be forced to cancel subscriptions to other abstracting and indexing tools ... "9 3. Who would be the beneficiaries of NLM price increases? Or, as Cummings and Mehnert succinctly concluded, "Et cui bono?" Apparently, Excerpta Medica believes its very survival is dependent on the NLM's prices. Will the taxpayer pay fewer taxes and, thus, benefit? It is doubtful that any political action committee would find this to be a worthy campaign issue, inasmuch as it would have no appreciable effect on tax revenues. Libraries clearly would not benefit, as already explained. Would the pharmaceutical industry derive some benefit? The industry currently pays the same rates as all other users, so it appears that it would be in a similar position. Excerpta Medica is asking the NLM to charge higher prices in order to recover its full costs. The NLM sees this as an artificial increase in prices. If the latter is correct, then it appears that Excerpta Medica essentially is trying to establish prices below which it and the NLM will not go. This is reminiscent of the fair-trade laws that existed during the past four decades. Clearly, the analogy breaks down, because the federal government (NLM) is involved, but the lesson to be learned from the experience of the now extinct fair-trade laws is that our society does not want artificially supported prices.
This editorial raises the question: What price are we willing to pay for scientific information? The answer is that we are willing to pay an equitable price, but it must not be at the expense of essential services from the science information industry.
